WO2023031615

WO2023031615 refers to a development program for monoclonal antibodies targeting the Lysophosphatidic acid receptor 1 (LPAR1), originally discovered by DJS Antibodies using its proprietary HEPTAD platform and subsequently acquired by AbbVie. These antibodies are designed to modulate or block LPAR1 signaling, a pathway implicated in various pathological states including fibrosis, inflammation, and oncogenesis. While DJS Antibodies' lead candidate DJS-002 focuses specifically on idiopathic pulmonary fibrosis (IPF) and NASH, the antibodies described under this patent application are being explored for a broader range of therapeutic applications. These include connective tissue diseases, digestive system disorders, neoplasms, nervous system diseases, and urogenital diseases. The program is currently in the discovery stage following AbbVie's acquisition of DJS Antibodies in 2022.

Other names

LPAR1 monoclonal antibody (DJS Antibodies)